AVEO Pharmaceuticals, Inc. (AVEO) Expected to Post Earnings of -$0.05 Per Share

Equities research analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings of ($0.05) per share for the current quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.06). AVEO Pharmaceuticals posted earnings per share of ($0.08) during the same quarter last year, which would suggest a positive year-over-year growth rate of 37.5%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.17) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.09). For the next year, analysts anticipate that the firm will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.26) to ($0.10). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover AVEO Pharmaceuticals.

Several research analysts have commented on the stock. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Tuesday, March 19th. HC Wainwright reissued a “hold” rating and set a $1.00 price target on shares of AVEO Pharmaceuticals in a research note on Monday, March 18th. FBR & Co set a $3.00 price target on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 20th. BidaskClub raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Finally, Robert W. Baird assumed coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, January 3rd. They set an “outperform” rating and a $3.00 price target on the stock. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $1.96.

Shares of AVEO stock traded down $0.01 during trading hours on Wednesday, hitting $0.57. 43,651 shares of the company’s stock were exchanged, compared to its average volume of 2,866,548. The company has a market capitalization of $84.79 million, a PE ratio of -3.00 and a beta of 1.11. AVEO Pharmaceuticals has a 12-month low of $0.49 and a 12-month high of $3.59.

Institutional investors have recently modified their holdings of the company. NEA Management Company LLC boosted its holdings in AVEO Pharmaceuticals by 11.8% in the fourth quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock valued at $33,434,000 after acquiring an additional 2,198,000 shares in the last quarter. BlackRock Inc. boosted its holdings in AVEO Pharmaceuticals by 3.3% in the fourth quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after acquiring an additional 236,822 shares in the last quarter. Vanguard Group Inc boosted its holdings in AVEO Pharmaceuticals by 1.5% in the third quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after acquiring an additional 73,519 shares in the last quarter. Vanguard Group Inc. boosted its holdings in AVEO Pharmaceuticals by 1.5% in the third quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after acquiring an additional 73,519 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in AVEO Pharmaceuticals by 36.3% in the fourth quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock valued at $2,231,000 after acquiring an additional 371,327 shares in the last quarter. Hedge funds and other institutional investors own 35.72% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Recommended Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.